Novartis reiterates its faith in Eylea rival Beovu; Anti-NGF drug from Lilly, Pfizer is accepted for FDA review
→ Last month, the Chicago-based American Society of Retina Specialists highlighted 14 cases of retinal vasculitis that have recently emerged with Regeneron’s Eylea rival — Novartis’ Beovu. Analysts also identified 36 serious cases reported to the FDA Adverse Event Reporting System, with 2 cases of vasculitis, 6 cases of blindness and 4 cases of eye inflammation. Novartis, which has previously said it had engaged an external safety review committee to look into these post-marketing safety concerns, issued a press release on Monday backing the drug, saying it believes the incidence of these events is consistent with the medicine’s package insert.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.